Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of (2-Benzhydryloxyethyl)Diethyl-Methylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.56 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.56 |
| ▸ | SCN1A | P35498 | 4/20 | 0.72 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.72 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefenidramium SCHEMBL16887882 | 0.82 | SCN1A (1.00) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| Mefenidramium SCHEMBL29519608 | 0.80 | SCN1A (0.96) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| Amoxydramine SCHEMBL29388859 | 0.79 | SCN1A (0.73) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL16884479 | 0.77 | SCN1A (0.71) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| Iodide SCHEMBL29375153 | 0.77 | SCN1A (0.84) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL1415333 | 0.75 | SLC6A2 (0.62) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL4667564 | 0.74 | SCN1A (0.65) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL4669231 | 0.71 | SLC6A2 (0.61) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL3992907 | 0.71 | SCN1A (0.55) | SCN1ASCN2ASCN3ACHRM1CHRM3 | |
| SCHEMBL4670218 | 0.71 | SCN1A (0.61) | SCN1ASCN2ASCN3ACHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | claimed |
| EP-3240539-A1 | CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Auspex Pharmaceuticals, Inc. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109362-A1 | CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| WO-2010080577-A2 | OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION | AUSPEX PHARMACEUTICAL, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| WO-2010075090-A2 | SCOPINE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100160271-A1 | BICYCLIC MODULATORS OF H1 RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20100160272-A1 | OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20100160347-A1 | PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-20100135956-A1 | STEROID MODULATORS OF PROGESTERONE RECEPTOR AND/OR GLUCOCORTICOID RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20100137268-A1 | PHTHALAZINONE MODULATORS OF H1 RECEPTORS AND/OR LTC4 RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| WO-2010060070-A2 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100130582-A1 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| WO-2010054158-A2 | STEROID MODULATORS OF GLUCOCORTICOID RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20100120733-A1 | STEROID MODULATORS OF GLUCOCORTICOID RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | claimed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM3, CHRM5, CHRM4 | CHRM1 5/4885CHRM3 1/4885SCN1A 1065/4885 |
| US-20100120733-A1 | STEROID MODULATORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, NR5A1 | CHRM1 1016/4885CHRM3 301/4885SCN1A 3018/4885 |
| US-20100144657-A1 | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS | OPRM1, OPRK1, OPRD1 | CHRM1 71/4885CHRM3 58/4885SCN1A 915/4885 |
| US-20100130582-A1 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | HTR2A, HTR3B, MTNR1A | CHRM1 133/4885CHRM3 70/4885SCN1A 2194/4885 |
| US-20100160272-A1 | OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION | HRH4, HRH2, HRH3 | CHRM1 107/4885CHRM3 103/4885SCN1A 2342/4885 |
| US-20100160347-A1 | PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION | CMA1, CPA3, KIT | CHRM1 924/4885CHRM3 735/4885SCN1A 1558/4885 |
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, TMEM120A | CHRM1 3497/4885CHRM3 748/4885SCN1A 464/4885 |
| US-20100137268-A1 | PHTHALAZINONE MODULATORS OF H1 RECEPTORS AND/OR LTC4 RECEPTORS | HRH4, HRH2, LTB4R | CHRM1 113/4885CHRM3 57/4885SCN1A 2530/4885 |
| US-20100160271-A1 | BICYCLIC MODULATORS OF H1 RECEPTORS | HRH2, HRH4, HRH1 | CHRM1 24/4885CHRM3 12/4885SCN1A 1173/4885 |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | OPRM1, OPRD1, OPRK1 | CHRM1 120/4885CHRM3 94/4885SCN1A 489/4885 |
| US-20100135956-A1 | STEROID MODULATORS OF PROGESTERONE RECEPTOR AND/OR GLUCOCORTICOID RECEPTOR | NR3C2, PGR, NR3C1 | CHRM1 875/4885CHRM3 275/4885SCN1A 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.